Search Results

You are looking at 71 - 80 of 295 items for :

  • "Neoadjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Prospective Study of Fertility Preservation in Young Women With Breast Cancer in Mexico

Cynthia Villarreal-Garza, Fernanda Mesa-Chavez, Alejandra Plata de la Mora, Melina Miaja-Avila, Marisol Garcia-Garcia, Alan Fonseca, Sylvia de la Rosa-Pacheco, Marlid Cruz-Ramos, Manuel Rolando García Garza, Alejandro Mohar, and Enrique Bargallo-Rocha

diagnosis but did not preserve fertility. A P value <.05 was significant. Statistical analysis was performed using SPSS Statistics, version 25 (IBM Corp). Additionally, the following time intervals were calculated: diagnosis to neoadjuvant chemotherapy

Full access

Oncology Research Program

Predicted Insensitive to Standard Neoadjuvant Chemotherapy, Including a Lead-in Cohort to Establish Activity in Patients With Metastatic TNBC Principal Investigator: Stacy Moulder, MD Co-Investigators: Senthil Damodaran, MD; Elizabeth Mittendorf, MD, PhD

Full access

Oncology Research Program

Triple-Negative Breast Cancer With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy, Including a Lead-in Cohort to Establish Activity in Patients With Metastatic TNBC Principal Investigator: Stacy Moulder, MD Co

Full access

Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer

Bharathi Muthusamy, Pradnya D. Patil, and Nathan A. Pennell

.96–2.09). Both stage II and III disease had improved OS (HR, 0.83; 95% CI, 0.73–0.95, and HR, 0.83; 95% CI, 0.72–0.94, respectively). 4 Despite meta-analyses showing a similar absolute survival benefit to adjuvant chemotherapy, use of neoadjuvant chemotherapy

Full access

The Cost of Initial Care for Medicare Patients With Advanced Ovarian Cancer

Renata R. Urban, Hao He, Rafael Alfonso-Cristancho, Melissa M. Hardesty, and Barbara A. Goff

between the diagnosis and surgery. Patients classified as receiving neoadjuvant chemotherapy consisted of those who had any claim for chemotherapy after a diagnosis of ovarian cancer and preceding claims for a surgical procedure for cancer. We also

Full access

Evolving Treatment Strategies for Triple-Negative Breast Cancer

Melinda Telli

phase II GeparSixto and CALGB 40603 trials took a different approach and set out to evaluate the role of carboplatin as an “add-on” to standard neoadjuvant chemotherapy in women with unselected triple-negative breast cancer. 1 , 2 According to the

Full access

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching

-negative breast cancer—current status and future directions . Ann Oncol 2009 ; 20 : 1913 – 1927 . 19901010 10.1093/annonc/mdp492 4. Chaudhary LN , Wilkinson KH , Kong A . Triple-negative breast cancer: who should receive neoadjuvant chemotherapy

Full access

Management of Locoregional Rectal Cancer

Christopher G. Willett

%, disease-free survival was 84%, and overall survival was 91%. The authors concluded that for selected patients with clinical stage I–III rectal cancer, neoadjuvant chemotherapy and selective RT does not seem to compromise outcomes. The randomized phase

Full access

The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer

Laura M. Spring, Yael Bar, and Steven J. Isakoff

addition of the platinum agent carboplatin to neoadjuvant chemotherapy (NACT) was consistently shown to increase pCR rates in multiple clinical trials. 11 – 13 According to a meta-analysis of 9 randomized trials, the incorporation of carboplatin

Full access

Letter to the Editor: Re: “Comparison of Treatment Strategies for Patients With Clinical Stage T1–3/N2 Lung Cancer”

Junmiao Wen and Donglai Chen

into 5 subgroups: surgery alone, surgery plus adjuvant chemotherapy with or without radiotherapy, neoadjuvant chemotherapy with or without radiotherapy plus surgery and adjuvant chemotherapy with or without radiotherapy, concurrent chemoradiotherapy